Prognostic Association of the Two-Cycle On-Treatment CRAFITY Score in Advanced HCC: A Single-Center Retrospective Cohort Study
Current Oncology · 2026
DOI: 10.3390/curroncol33100598 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Current Oncology, 2026. Verfasst von Xiaochun Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Oncology, Zhongshan Hospital (Xiamen), Fudan University, Xiamen 361015, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, C-Reactive Protein, alpha-Fetoproteins. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: *Clinical Research Center for Precision Medicine of Abdominal Tumors of Fujian Province.
Abstract (Originalsprache)
The baseline CRAFITY score, derived from AFP and C-reactive protein, is a validated prognostic biomarker for hepatocellular carcinoma (HCC) patients receiving immunotherapy. However, whether its prognostic value can be improved by on-treatment reassessment remains unclear. We evaluated the two-cycle on-treatment CRAFITY score in 108 advanced-HCC patients who received immune-based combination therapy as first- or second-line treatment. The score was calculated at baseline and after two cycles. Kaplan–Meier, Cox regression, time-dependent ROC, landmark, and sensitivity analyses were performed. The two-cycle score significantly stratified overall survival (median OS from landmark: 34.6, 12.9, and 6.7 months for scores 0, 1, and 2; p < 0.0001) and remained independently associated with OS after adjustment for vascular invasion, treatment line, and concomitant transarterial chemoembolization (TACE) (HR 2.36, 95% CI 1.70–3.29, p < 0.001). The baseline score showed only borderline associations (OS p = 0.07; PFS p = 0.09). The two-cycle score had an apparent AUC of 0.709 (95% CI 0.586–0.832) at 6 months and 0.745 (95% CI 0.658–0.832) at 12 months. The corresponding values for the baseline score were 0.645 and 0.638. Adding the two-cycle score to a clinical reference model increased the 12-month AUC from 0.699 to 0.811 (ΔAUC = 0.112). Bootstrap internal validation yielded an optimism-corrected C-index of 0.698 (95% CI 0.650–0.776). In conclusion, the two-cycle CRAFITY score provides complementary posttreatment prognostic information for early risk stratification, but prospective external validation is required before clinical application.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary Oncology, Zhongshan Hospital (Xiamen), Fudan University, Xiamen 361015, China.
- Xiamen Clinical Research Center for Cancer Therapy, Xiamen 361015, China.
- Fujian Provincial Clinical Research Center for Precision Medicine of Abdominal Tumors, Xiamen 361015, China.
ORCID-Profile: Guobin Chen, Yanfang Wu, Hong Chen, Zhenzhen Zhang
Förderung
- *Clinical Research Center for Precision Medicine of Abdominal Tumors of Fujian Province
Zitieren
APA
Chen, X., Guo, X., Chen, G., Zheng, S., Wu, Y., Wu, J., Chen, H., Zhang, Z., & Zhang, B. (2026). Prognostic Association of the Two-Cycle On-Treatment CRAFITY Score in Advanced HCC: A Single-Center Retrospective Cohort Study. Current Oncology. https://doi.org/10.3390/curroncol33100598
Vancouver
Chen X, Guo X, Chen G, Zheng S, Wu Y, Wu J, et al. Prognostic Association of the Two-Cycle On-Treatment CRAFITY Score in Advanced HCC: A Single-Center Retrospective Cohort Study. Current Oncology. 2026. doi:10.3390/curroncol33100598
BibTeX
@article{Chen2026,
author = {Chen, Xiaochun and Guo, Xinkun and Chen, Guobin and Zheng, Susu and Wu, Yanfang and Wu, Jingfang and Chen, Hong and Zhang, Zhenzhen and Zhang, Boheng},
title = {Prognostic Association of the Two-Cycle On-Treatment CRAFITY Score in Advanced HCC: A Single-Center Retrospective Cohort Study},
journal = {Current Oncology},
year = {2026},
doi = {10.3390/curroncol33100598}
}
EUVIMED